- Home
- Products
- Customized FluoroAb™
- ERBB2
- Margetuximab-Cy3
Margetuximab-Cy3 (CAT#: ADC-FL-1364)
This product is comprised of an anti-ERBB2 monoclonal antibody (Margetuximab) labeled with cy3. cy3 is a orange-fluorescent dye and it's excitation/emission is 554/568 nm.
- TARGET
- ANTIBODY
- DYE
- Name
- ERBB2
- Alternative Names
- ERBB2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian); NGL, v erb b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog); receptor tyrosine-prEGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown he
- Overview
- This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
- Overview
- Chimeric Anti-ERBB2 IgG1-kappa antibody,Margetuximab
- Generic name
- Margetuximab
- Species Reactivity
- Human
- Name
- Cy3
- Color
- Orange
- Excitation⁄Emission (nm)
- 554/568
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-FL-1364. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-2597 | Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-1115 | Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-1110 | Anti-ERBB2 (Margetuximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-1116 | Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-1114 | Anti-ERBB2 (Pertuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-PDCD1 MAb (Clone 16)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS12229)
- Visilizumab-iFluor 532 (CAT#: ADC-FL-580)
- Anti-FCER2 MAb (Clone 1)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS4832)
- Anti-BSG MAb (Clone 2)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS14670)
- Anti-SOST MAb (Clone 3)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS9182)
- Anti-EGFR MAb (Clone 2)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS10970)
- Anti-CD5 MAb (Clone 11)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS4276)
- Anti-IL13 MAb (Clone 5)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS1304)
- Anti-CD33 MAb (Clone 24)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS11799)
- Gantenerumab-Fluoresein (CAT#: ADC-FL-106)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.